In this Dec. 12, 2019 photo provided by Biogen, a scientist works on Alzheimer’s disease research in a laboratory at the drugmaker’s headquarters in Cambridge, Mass. On Friday, Nov. 6, 2020, a panel of outside experts will meet to advise the Food and Drug Administration on the drug, called aducanumab from Biogen Inc. and Japan’s Eisai Co. The drug does not cure or reverse Alzheimer’s; the claim is that it modestly slows the rate of decline. (David A. White/Biogen via AP)
Government health advisers sharply criticized a closely watched Alzheimer’s drug on Friday, concluding there wasn’t enough evidence that the experimental drug slowed the brain-destroying disease.
На данный момент можно найти площадку с играми, где есть карточные и настольные игры, новейших и топовых автоматов, мгновенных игр и лайв-игр с live-дилерами....
